All In Biotech

Drug Trial Radar · NCT06669754

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

85

Actual

Start

Dec 1, 2024

Primary completion

Jul 21, 2026

Study completion Jul 21, 2026

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DeucrictibantDrug

    Deucrictibant 40mg extended-release tablet for once daily oral use

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-normalized (per 4 weeks) number of Investigator-confirmed HAE attacks during the 24-week Treatment PeriodTime frame: 24 weeks

Locations

56 sites in 24 countries. Site status is shown where the registry gives one.

  • Study Site

    Little Rock, Arkansas

  • Study Site

    San Diego, California

  • Study site

    Santa Monica, California

  • Study site

    Walnut Creek, California

  • Study Site

    Chevy Chase, Maryland

  • Study Site

    St Louis, Missouri

  • Study Site

    Corrientes, Argentina

  • Study Site

    San Martin, Argentina

  • Study Site

    Santo André, Brazil

  • Study Site

    Sofia, Bulgaria

  • Study Site

    Sofia, Bulgaria

  • Study Site

    Edmonton, Canada

  • Study Site

    Ottawa, Canada

  • Study Site

    Grenoble, France

  • Study Site

    Lille, France

  • Study Site

    Berlin, Germany

  • Study Site

    Frankfurt, Germany

  • Study Site

    Hanover, Germany

  • Study Site

    Hong Kong, Hong Kong

  • Study Site

    Budapest, Hungary

  • Study Site

    Dublin, Ireland

  • Study Site

    Milan, Italy

  • Study Site

    Padova, Italy

  • Study Site

    Kawasaki, Japan

  • Study Site

    Tokyo, Japan

  • Study Site

    Tokyo, Japan

  • Study Site

    Auckland, New Zealand

  • Study Site

    Krakow, Poland

  • Study Site

    San Juan, Puerto Rico

  • Study Site

    Sângeorgiu de Mureş, Romania

  • Study Site

    Singapore, Singapore

  • Study Site

    Martin, Slovakia

  • Study Site

    Cape Town, South Africa

  • Study Site

    Daegu, South Korea

  • Study Site

    Seoul, South Korea

  • Study Site

    Seoul, South Korea

  • Study Site

    Suwon, South Korea

  • Study Site

    Barcelona, Spain

  • Study Site

    Barcelona, Spain

  • Study Site

    Seville, Spain

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.